Literature DB >> 1643291

The evidence for interleukin-6 as an autocrine growth factor in malignancy.

S Akira1, T Kishimoto.   

Abstract

Interleukin-6, IL-6, is a pleiotropic cytokine which plays a central role in defense mechanisms, including the immune response, acute phase reaction and hematopoiesis. Abnormal expression of the IL-6 gene has been suggested to be involved in the pathogenesis of a variety of diseases, especially rheumatoid arthritis, Castleman's disease, mesangial proliferative glomerulonephritis, multiple myeloma and Kaposi's sarcoma. In the case of multiple myeloma and Kaposi's sarcoma, the existence of an IL-6-IL-6 receptor autocrine loop has been implicated in the oncogenesis process. On the other hand, IL-6 has a potent anti-tumor activity against certain types of tumors. This anti-tumor effect is mediated by in vivo induction of tumor specific cytotoxic T cells and in part by a growth inhibitory activity of IL-6.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1643291

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  10 in total

Review 1.  The role of chalcones in suppression of NF-κB-mediated inflammation and cancer.

Authors:  Vivek R Yadav; Sahdeo Prasad; Bokyung Sung; Bharat B Aggarwal
Journal:  Int Immunopharmacol       Date:  2010-12-22       Impact factor: 4.932

Review 2.  The role of microRNAs in hepatocarcinogenesis: current knowledge and future prospects.

Authors:  Motoyuki Otsuka; Takahiro Kishikawa; Takeshi Yoshikawa; Motoko Ohno; Akemi Takata; Chikako Shibata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2013-11-21       Impact factor: 7.527

3.  EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.

Authors:  Timothy D Clay; Prudence A Russell; Hongdo Do; Vijaya Sundararajan; Matthew Conron; Gavin M Wright; Benjamin Solomon; Alexander Dobrovic; Sue-Anne McLachlan; Melissa M Moore
Journal:  Med Oncol       Date:  2017-09-06       Impact factor: 3.064

4.  GLI2 transcription factor mediates cytokine cross-talk in the tumor microenvironment.

Authors:  Sherine F Elsawa; Luciana L Almada; Steven C Ziesmer; Anne J Novak; Thomas E Witzig; Stephen M Ansell; Martin E Fernandez-Zapico
Journal:  J Biol Chem       Date:  2011-03-18       Impact factor: 5.157

5.  CNTF and its receptor subunits in human gliomas.

Authors:  J Weis; L M Schönrock; S L Züchner; D C Lie; U Sure; C Schul; F Stögbauer; E B Ringelstein; H Halfter
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

6.  Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.

Authors:  Zhenhua Xu; Esther Bouman-Thio; Craig Comisar; Bart Frederick; Bart Van Hartingsveldt; Joseph C Marini; Hugh M Davis; Honghui Zhou
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

7.  A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus.

Authors:  R Sun; S F Lin; L Gradoville; Y Yuan; F Zhu; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

Review 8.  Cytokines in the microenvironment of Waldenström's macroglobulinemia.

Authors:  Sherine F Elsawa; Stephen M Ansell
Journal:  Clin Lymphoma Myeloma       Date:  2009-03

9.  Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.

Authors:  T Nakano; A P Chahinian; M Shinjo; A Tonomura; M Miyake; N Togawa; K Ninomiya; K Higashino
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

10.  The nuclear factor-κB correlates with increased expression of interleukin-6 and promotes progression of gastric carcinoma.

Authors:  Yefeng Yin; Xiulian Si; Yan Gao; Lei Gao; Jiangning Wang
Journal:  Oncol Rep       Date:  2012-10-19       Impact factor: 3.906

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.